97
Participants
Start Date
December 4, 2020
Primary Completion Date
September 30, 2024
Study Completion Date
September 30, 2024
Genetic: AAV5-hRKp.RPGR
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
Genetic: AAV5-hRKp.RPGR
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)
Universite de Lausanne, Hopital ophtalmique Jules-Gonin, Lausanne
Rigshospitalet Glostrup, Glostrup Municipality
University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical, Basel
UZ Gent, Ghent
University of Pittsburgh Medical Center (UPMC), Pittsburgh
Ospedale San Paolo, Milan
Duke Eye Center, Durham
Hosp Univ Fund Jimenez Diaz, Madrid
Emory University, Atlanta
VitreoRetinal Associates, PA, Gainesville
Univ of Michigan Medical Center, Ann Arbor
Azienda Ospedaliero Universitaria Careggi, Florence
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris
Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli, Napoli
Childrens Hospital, Los Angeles
Hadassah Medical Center, Jerusalem
Stanford Health Care, Palo Alto
Shiley Eye Institute Jacobs Retina Center, La Jolla
Massachusetts General Hospital - Center for Celiac Research and Treatment, Boston
Hospital For Sick Children, Toronto
IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS, Roma
VUMC Amsterdam, Amsterdam
Radboudumc, Nijmegen
NHS Lothian, Edinburgh
Gartnavel General Hospital, Glasgow
St James University Hospital, Leeds
Moorfields Eye Hospital, London
Janssen Research & Development, LLC
INDUSTRY